Mechanism of action
Dapagliflozin selectively inhibits sodium-glucose cotransporter-2 (SGLT2) in the proximal convoluted tubule of the nephron. Under normal physiology, SGLT2 is responsible for reabsorbing approximately 90% of filtered glucose from the glomerular filtrate back into the bloodstream.
By blocking SGLT2, dapagliflozin prevents renal glucose reabsorption, leading to urinary glucose excretion (glycosuria) of 50–80 grams per day when blood glucose exceeds the renal threshold. This mechanism lowers plasma glucose independent of insulin secretion or insulin sensitivity, making it effective across the spectrum of type 2 diabetes.
Cardiovascular and renal benefits extend beyond glucose lowering and include:
- Mild osmotic diuresis and natriuresis, reducing preload and blood pressure
- Decreased intraglomerular pressure by restoring tubuloglomerular feedback
- Metabolic shift favoring ketone body utilization and improved myocardial energetics
- Reduction in epicardial adipose tissue and systemic inflammation
- Direct effects on cardiac fibrosis and remodeling (mechanisms under investigation)
These pleiotropic effects explain the drug's efficacy in heart failure and chronic kidney disease, even in patients without diabetes.
- Dapagliflozin inhibits SGLT2 in the proximal tubule, causing glycosuria and lowering glucose independent of insulin.
- Approved for type 2 diabetes, heart failure (HFrEF and HFpEF), and chronic kidney disease regardless of diabetes status.
- Euglycemic diabetic ketoacidosis (DKA with glucose <250 mg/dL) is a serious adverse effect; hold before surgery.
- Most common adverse effects are genital mycotic infections and urinary tract infections due to glycosuria.
- Reduces heart failure hospitalization and slows CKD progression independent of glycemic control.
- Causes mild osmotic diuresis leading to volume depletion, hypotension, and transient eGFR decrease.
- Fournier gangrene is a rare but life-threatening complication requiring emergency surgical intervention.
- Contraindicated in severe renal impairment (eGFR <25) and dialysis patients at initiation.
Indications
Dapagliflozin is FDA-approved for multiple cardiovascular and metabolic conditions:
Type 2 diabetes mellitus
Used as monotherapy (if metformin contraindicated or not tolerated) or in combination with other antihyperglycemic agents including metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, and insulin. Reduces HbA1c by approximately 0.5–1.0% and promotes modest weight loss (2–3 kg) through caloric loss in urine.
Heart failure
- Heart failure with reduced ejection fraction (HFrEF, EF ≤40%): Reduces hospitalizations and cardiovascular death regardless of diabetes status (DAPA-HF trial).
- Heart failure with preserved ejection fraction (HFpEF, EF >40%): Approved based on the DELIVER trial showing reduced heart failure events across the ejection fraction spectrum.
Chronic kidney disease
Indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of progression (DAPA-CKD trial). Benefits observed in patients with and without type 2 diabetes, with eGFR ≥25 mL/min/1.73 m² and albuminuria.
Off-label uses include polycystic kidney disease (under investigation) and adjunctive therapy in type 1 diabetes (not FDA-approved due to DKA risk).
Pharmacokinetics
- Absorption: Rapidly absorbed with peak plasma concentration at 1–2 hours; bioavailability is 78%. Can be taken with or without food.
- Distribution: Volume of distribution ~118 L; approximately 91% protein-bound (mainly to albumin).
- Metabolism: Hepatic metabolism via UGT1A9 to inactive metabolites; minimal CYP450 involvement.
- Excretion: Approximately 75% excreted in urine (1.5% unchanged), 21% in feces. Half-life is approximately 12.9 hours, allowing once-daily dosing.
- Special populations: Dose adjustment not required for mild-to-moderate hepatic impairment or mild-to-moderate renal impairment. Efficacy for glycemic control diminishes with eGFR <45 mL/min/1.73 m², but cardiovascular and renal benefits persist down to eGFR 25.
Adverse effects
Common
- Genital mycotic infections (vulvovaginal candidiasis, balanitis): occur in 5–10% of patients, more common in women and uncircumcised men. Usually mild and respond to topical antifungals.
- Urinary tract infections: increased frequency due to glycosuria; symptoms include dysuria and frequency.
- Volume depletion: orthostatic hypotension, dizziness, syncope, especially in elderly patients, those on diuretics, or with baseline hypotension.
- Increased urination (polyuria) due to osmotic diuresis and glycosuria.
- Nasopharyngitis and back pain reported in clinical trials.
Serious
- Euglycemic diabetic ketoacidosis (euDKA): DKA with blood glucose <250 mg/dL, often precipitated by illness, reduced caloric intake, surgery, or insulin dose reduction. Presents with nausea, vomiting, abdominal pain, and malaise; high anion gap metabolic acidosis with ketonemia. Requires high index of suspicion.
- Acute kidney injury: risk increased in setting of volume depletion, hypotension, or concurrent nephrotoxic drugs (NSAIDs, ACE inhibitors, diuretics).
- Fournier gangrene (necrotizing fasciitis of the perineum): rare but life-threatening; FDA warning issued in 2018. Presents with severe perineal pain, fever, and tenderness. Requires emergency surgical debridement.
- Hypoglycemia: risk is low when used as monotherapy but increases when combined with insulin or sulfonylureas.
- Lower limb amputations: signal detected in CANVAS trial (canagliflozin), not consistently observed with dapagliflozin; causality uncertain.
Metabolic
- Small increases in LDL cholesterol (3–5 mg/dL) and HDL cholesterol.
- Transient increases in serum creatinine (usually <0.3 mg/dL) and hematocrit due to hemoconcentration; typically reverse after discontinuation.
Contraindications and warnings
Absolute contraindications
- Severe hypersensitivity reaction (anaphylaxis, angioedema) to dapagliflozin or any component.
- Patients on dialysis or with eGFR <25 mL/min/1.73 m² (initiation not recommended; may continue if already on therapy and tolerating).
Warnings and precautions
- Volume depletion: assess volume status before initiation, especially in elderly (≥65 years), patients with impaired renal function (eGFR 30–60), or those taking loop diuretics. Consider temporarily discontinuing dapagliflozin during acute illness causing reduced oral intake or fluid losses.
- Ketoacidosis risk: avoid in type 1 diabetes (not approved). Educate patients to discontinue before elective surgery or prolonged fasting and to monitor for symptoms of ketoacidosis even if glucose is normal. Risk factors include insulin deficiency, caloric restriction, alcohol use, and acute illness.
- Pregnancy and lactation: Category C; limited human data. Not recommended during the second and third trimesters due to potential renal effects on the fetus. Insulin is preferred for diabetes management during pregnancy. Unknown if excreted in breast milk.
- Hypotension: use caution in patients with baseline SBP <110 mmHg.
- Bladder cancer: no consistent signal in meta-analyses, but avoid in patients with active bladder cancer; weigh risk/benefit in history of bladder cancer.
- Bone fracture: no increased risk observed with dapagliflozin (unlike some other SGLT2 inhibitors).
Drug-specific considerations
Patients should be counseled on recognizing signs of genital and urinary infections and maintaining adequate hydration.
Drug interactions
Dapagliflozin has a low potential for clinically significant drug-drug interactions due to minimal CYP450 involvement.
Moderate interactions
- Insulin and insulin secretagogues (sulfonylureas, meglitinides): increased risk of hypoglycemia. Dose reduction of insulin or secretagogue may be required when initiating dapagliflozin.
- Diuretics (loop, thiazide): additive volume depletion and hypotension. Monitor volume status and blood pressure; consider dose adjustment of diuretic.
- Antihypertensives: potential for additive blood pressure lowering.
Minor interactions
- UGT inducers (rifampin, phenytoin, phenobarbital): may decrease dapagliflozin exposure, potentially reducing efficacy. Dose adjustment not routinely recommended.
- NSAIDs: may increase risk of acute kidney injury, especially when combined with ACE inhibitors or ARBs (triple whammy). Use with caution and monitor renal function.
Lithium
SGLT2 inhibitors may reduce lithium levels due to increased renal clearance; monitor lithium concentrations and adjust dose as needed.
Positive drug-drug synergy
Combination with metformin, GLP-1 receptor agonists, and DPP-4 inhibitors provides complementary mechanisms without overlapping toxicity and is commonly used in type 2 diabetes management.
Clinical pearls
- Euglycemic DKA is the most high-yield complication: Always maintain a high index of suspicion in patients presenting with nausea, vomiting, and malaise, even if blood glucose is normal or only mildly elevated. Check serum or urine ketones and anion gap.
- Hold before surgery: Discontinue dapagliflozin at least 3 days before scheduled surgery or procedures requiring prolonged fasting to reduce DKA risk.
- Cardiovascular and renal benefits are independent of glycemic effects: SGLT2 inhibitors reduce heart failure hospitalization and slow CKD progression in non-diabetic patients, making them foundational therapy in these populations.
- Initial eGFR dip is expected and not harmful: A transient decrease in eGFR (5–10 mL/min) within the first weeks of therapy is hemodynamic and reversible; it reflects reduced intraglomerular pressure and predicts long-term renal protection. Do not discontinue prematurely.
- Genital infections are common but manageable: Counsel patients proactively; most infections are mild and respond to topical therapy. Recurrent infections may require discontinuation.
- Weight loss and blood pressure reduction are "bonus" benefits: Average weight loss is 2–3 kg; SBP reduction is 3–5 mmHg, beneficial in overweight hypertensive patients.
- Not first-line for glycemic control alone: Despite HbA1c reduction, metformin remains first-line monotherapy for type 2 diabetes unless contraindicated. Dapagliflozin is preferred add-on therapy in patients with established cardiovascular disease, heart failure, or CKD.
- Laboratory monitoring: Check eGFR and electrolytes at baseline and periodically. Monitor for signs of volume depletion, especially in hot weather or acute illness.
SGLT-2 Side effects: Sugar in urine (glycosuria), Genital infections, Low BP (volume depletion), Thirst/polyuria, Ketoacidosis (euglycemic)
Practice questions
1. A 62-year-old woman with type 2 diabetes presents to the emergency department with nausea, vomiting, and abdominal pain for 2 days. She recently started a new diabetes medication. Her blood glucose is 180 mg/dL. Vital signs: BP 105/70 mmHg, HR 110 bpm. Labs show anion gap of 22 mEq/L, bicarbonate 12 mEq/L, and positive serum ketones. Which medication is most likely responsible?
2. A 58-year-old man with heart failure with reduced ejection fraction (EF 30%) and no diabetes is started on dapagliflozin. Two weeks later, his creatinine increases from 1.2 to 1.5 mg/dL (eGFR drops from 62 to 50 mL/min/1.73 m²). He feels well with stable weight and blood pressure. What is the most appropriate next step?
3. A 55-year-old woman with type 2 diabetes treated with metformin and dapagliflozin presents with severe perineal pain, fever (39°C), and erythema extending from the perineum to the inner thighs. Examination reveals crepitus and foul-smelling discharge. What is the most likely diagnosis?
Frequently asked questions
How does dapagliflozin work?
Dapagliflozin blocks SGLT2 receptors in the kidney's proximal tubule, preventing reabsorption of glucose and causing it to be excreted in the urine (glycosuria). This lowers blood sugar independent of insulin and also produces mild diuresis, reducing blood pressure and cardiovascular strain. The mechanism provides benefits in heart failure and chronic kidney disease beyond glucose control.
What are the side effects of dapagliflozin?
Common side effects include genital yeast infections (5–10%), urinary tract infections, increased urination, and dizziness from volume depletion. Serious but rare adverse effects include euglycemic diabetic ketoacidosis (DKA with normal glucose), acute kidney injury, and Fournier gangrene (necrotizing infection of the perineum). Patients may also experience transient increases in creatinine and small increases in LDL cholesterol.
Is dapagliflozin used only for diabetes?
No, dapagliflozin is approved for heart failure with reduced or preserved ejection fraction and chronic kidney disease, even in patients without diabetes. Clinical trials showed it reduces heart failure hospitalizations and slows kidney disease progression independent of glucose-lowering effects. It has become a cornerstone therapy in cardiology and nephrology for these indications.
What is euglycemic DKA and why does dapagliflozin cause it?
Euglycemic DKA is diabetic ketoacidosis with blood glucose below 250 mg/dL, making it easy to miss. Dapagliflozin promotes ketone production by shifting metabolism and excretes glucose in urine, masking hyperglycemia. Triggers include surgery, fasting, illness, or insulin reduction. Patients present with nausea, vomiting, and abdominal pain; diagnosis requires checking ketones and anion gap even when glucose appears normal.
Dapagliflozin vs empagliflozin — what is the difference?
Both are SGLT2 inhibitors with similar mechanisms, efficacy, and side effect profiles, including benefits in heart failure and CKD. Dapagliflozin is approved for both HFrEF and HFpEF, while empagliflozin initially had HFrEF approval and later expanded. Pharmacokinetics differ slightly (dapagliflozin metabolized via UGT1A9, empagliflozin minimally metabolized), but clinical differences are minimal. Choice often depends on formulary and clinician familiarity.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A10BK01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.